Development of technology and capabilities critical for clinical translation of first of its kind brain tumour therapy

开发对首个脑肿瘤疗法的临床转化至关重要的技术和能力

• 批准号: 10048434
• 金额: $ 76.86万
• 依托单位: QV BIOELECTRONICS LTD
• 依托单位国家: 英国
• 项目类别: Investment Accelerator
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10048434
• 关键词: Development; technology; capabilities; critical; clinical

Glioblastoma is the most common and aggressive primary adult brain cancer. Global incidence is 3-5/100,000 persons and rising, with c.3000 UK diagnoses/year. There is no cure and the 5-year survival rate is ~3.4%.Electric Field therapy (EFT) is a new form of cancer treatment applied after tumour resection that directly interferes with cell division, slowing tumour recurrence and prolonging life. However, the only available electrotherapy device for glioblastoma is not recommended for use on the NHS by NICE due to poor patient quality-of-life and low cost-effectiveness.QV Bioelectronics (QVB) is developing GRACE, a first of its kind implanted EFT device. GRACE delivers EFT in a focal and continuous manner that will potentially double glioblastoma patient life expectancy, leading to up to 10-times higher 5-year survival rates whilst overcoming quality-of-life issues associated with the existing EFT treatment. QVB have demonstrated initial safety during preclinical development, with pre-clinical efficacy testing taking place in parallel to this project. As part of this project, QVB aims to carry out additional development steps to ensure GRACE will be ready for 1st in human trials in UK patients by the end of 2024\.QVB's device is still undergoing pre-clinical development and will not be ready to be prescribed to patients for several years. QVB's technology will be expanded to other types of brain tumours in future, with our research and innovation hub creating a significant number of jobs in the UK, creating a combined global market opportunity worth over £3.9Bn/year. This will cement the UK's position as global leaders in the growing field of bioelectronics.

胶质母细胞瘤是最常见和侵略性的原发性成人脑癌。全球事件为3-5/100,000人，并且有上升，每年诊断为3000 c.3000。无法治愈，5年的存活率约为3.4％。电力野外治疗（EFT）是一种新的癌症治疗形式，在肿瘤切除后采用了直接干扰细胞分裂的癌症治疗，从而减慢了肿瘤复发和延长寿命。但是，由于患者生活质量差和成本效益低，不建议在NHS上使用唯一可用的用于胶质母细胞瘤的电子疗法。QVBioelectronics（QVB）正在开发Grace，这是一种植入的EFT设备。 Grace以局灶性和连续的方式提供EFT，这可能会导致双胶质母细胞瘤患者的预期寿命，从而导致高达10倍的5年生存率，同时克服与现有EFT治疗相关的生活质量问题。 QVB在临床前开发过程中证明了最初的安全性，临床前效率测试与该项目并行进行。作为该项目的一部分，QVB旨在执行其他开发步骤，以确保在2024年底之前为英国患者的人类试验准备恩典，\ .qvb的设备仍在进行临床前开发，并且将不愿意向患者开处方数年。 QVB的技术将来将扩展到其他类型的脑肿瘤，而我们的研究和创新中心在英国创造了大量的就业机会，从而创造了价值超过39亿英镑/年的全球市场机会。这将巩固英国在不断增长的生物电子领域的全球领导者的地位。